Recent Updates
Recently added Catalysts
ZLAB

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Wednesday, October 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
Price reaction · baseline $24.79 (2024-10-15 close) · hit after-hours · 2 other ZLAB headline(s) in the window, move may be shared
day 0 close
+5.6%
day 1
+6.3%
day 3 · peak
+12.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer

Full Press Release Details

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024.
ShareAdd on Google
Tags: ZLAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 16, 2024

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~28 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Small-cell Lung Cancer →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →